Labiotech.eu

Interview 21 Apr 2021

Changing Attitudes on Vaccine and Public Health Investment

The Covid-19 pandemic has pushed investment and research into vaccines and public health, but will such interest continue in the long term? Glenn Rockman, founder and Managing Partner of Adjuvant Capital, a VC firm investing in the infectious disease area, believes it will. Rockman did not plan to get into life science investment. With a […]

April 21, 2021 - 5 minutesmins - By Helen Albert

cardiovascular disease amarin vascepa vazkepa

News and Trends 21 Apr 2021

Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain

Last month’s EU approval of Vazkepa — a treatment derived from fish oil and branded as Vascepa in the US — has added much-needed ammunition to the arsenal of doctors battling cardiovascular disease. Yet other similar treatments are returning lukewarm results and the possibility of approvals being withdrawn hangs in the air. Icosapent ethyl, a […]

April 21, 2021 - 5 minutesmins - By Victor Kotsev

News and Trends 20 Apr 2021

Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions

The US medtech firm Hologic has bought the Finnish-French biotech Mobidiag for around €668M in the latest of a series of mergers, acquisitions, and stock market launches taking over the diagnostics market. Hologic’s move is the latest in a flurry of activity from the women’s health specialist, which has snapped up Diagenode in Belgium, Biotheranostics […]

April 20, 2021 - 5 minutesmins - By Anita Chakraverty

Opinion 19 Apr 2021

The Hidden Costs of Mismanaged R&D Projects in Biotech and Pharma

Mismanagement of R&D projects in biotech and pharma is more common than one might think and can result in high development costs and eventual clinical failure. Can we do something about it? Biotechnology and pharmaceutical businesses are synonymous with both a high risk and an even bigger investment. Bringing new drugs to the market can […]

April 19, 2021 - 7 minutesmins - By Auste Kanapeckaite

neoantigen immuno oncology cancer therapy achilles therapeutics

News and Trends 15 Apr 2021

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

The close of the UK firm Achilles Therapeutics’ €146.9M ($175.5M) initial public offering last month may have been a long-delayed starter pistol for investments into neoantigen-based therapies, a family of personalized cancer immunotherapies that target proteins unique to an individual’s tumor. Neoantigen-focused companies have closed smaller initial public offerings (IPOs) in the past. Two major […]

April 15, 2021 - 5 minutesmins - By Mark Zipkin

peanut allergy treatment DBV Technologies Aimmune Viaskin Palforzia

News and Trends 14 Apr 2021

DBV Battles Aimmune for Share of Peanut Allergy Treatment Market

Last year, the FDA rejected DBV Technologies’ peanut allergy treatment and approved that of its rival Aimmune. After recent talks with the FDA and EMA, DBV has laid out a comeback plan that could carve it a niche in the peanut allergy treatment market. The French biotech firm DBV is coming back from a snub by […]

April 14, 2021 - 5 minutesmins - By External Contributor

Interview 5 Apr 2021

Base Editing: The Next Frontier in Genome Editing Technology

Jonathan Frampton, Corporate Development Partner at Horizon Discovery, a Perkin Elmer company, shares his insights into the promises of base editing technology. In less than a decade, the advent of CRISPR-Cas9 has made gene editing easier and faster than ever. But CRISPR, as well as earlier genome editing tools, have a series of technical limitations, […]

April 5, 2021 - 4 minutesmins - By Larissa Warneck-Silvestrin

News and Trends 1 Apr 2021

Have European Investors Missed the Exosome ‘Gold Rush’?

When Oxford-based Evox Therapeutics announced its €81.1M (£69.2M) Series C round in February, it signaled that investors are taking exosome therapies seriously. But a lack of European investors in the exosome field raises the very real possibility that the best opportunities have already passed, along with the chance to build an exosome ecosystem to rival […]

April 1, 2021 - 5 minutesmins - By Mark Zipkin

VC finance stock funds ipo gamma delta t cell lava therapeutics

News and Trends 31 Mar 2021

Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells

The Dutch biotech startup Lava Therapeutics launched onto the Nasdaq stock market last week with an €85.6M ($100.5M) IPO. This is a sign of mounting investor interest in cancer treatments based on immune cells known as gamma delta T cells. The proceeds of the IPO will be used to drive the development of the company’s […]

March 31, 2021 - 5 minutesmins - By Anita Chakraverty

In Depth 31 Mar 2021

Equity Crowdfunding for Biotech Startups: Does It Work?

In the last decade, crowdfunding has become a popular way to finance all sorts of projects and products. Biotech is no exception, but many question whether the high risk and long term nature of investing in the biotech industry makes it a good fit for equity crowdfunding. When you hear the term crowdfunding, you might […]

March 31, 2021 - 9 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 29 Mar 2021

The 25 Best Biotech Incubators Hatching Startup Stars in Europe

Incubators can give biotech startups the boost they need to get off the ground. These are our top picks of the biotech incubators across Europe supporting the next generation of life science startups. Creating a biotech company is a challenging, long-term endeavor. In particular, the first steps can be essential to set up a new […]

March 29, 2021 - 9 minutesmins - By Clara Rodríguez Fernández

News and Trends 25 Mar 2021

Covid-19 Vaccine Approvals Bring Hope and Challenges for Adenoviral Technology

The rise of adenoviral Covid-19 vaccines highlights the potential of companies using similar technology in other fields like cancer or gene therapy. However, complex challenges remain, such as circumventing immunity to adenoviral treatments. Earlier this month, Johnson & Johnson’s candidate became the first single-shot Covid-19 vaccine to get the EMA green light. The vaccine is […]

March 25, 2021 - 6 minutesmins - By Victor Kotsev

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Changing Attitudes on Vaccine and Public Health Investment

Vazkepa Gets EMA Nod for Cardiovascular Disease, But Hurdles Remain

Pandemic Boosts Diagnostics Field with High Revenues and Acquisitions

The Hidden Costs of Mismanaged R&D Projects in Biotech and Pharma

Achilles Therapeutics’ IPO Caps Investment Wave for Neoantigens

DBV Battles Aimmune for Share of Peanut Allergy Treatment Market

Base Editing: The Next Frontier in Genome Editing Technology

Have European Investors Missed the Exosome ‘Gold Rush’?

Lava Therapeutics’ IPO Shakes Cancer Niche of Gamma Delta T Cells

Equity Crowdfunding for Biotech Startups: Does It Work?

The 25 Best Biotech Incubators Hatching Startup Stars in Europe

Covid-19 Vaccine Approvals Bring Hope and Challenges for Adenoviral Technology

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!